Phaseline

Targets › KAT6B

KAT6B (Histone acetyltransferase KAT6B): drug programs, companies and trials

4 programs from 4 companies in 6 trials: 4 Phase 1, 1 Phase 3, 1 Phase 2; Oncology, Hematology; next expected readout Dec 2026.

Histone acetyltransferase which may be involved in both positive and negative regulation of transcription. Required for RUNX2-dependent transcriptional activation. (UniProt, Q8WYB5)

Open in Phaseline: the race on KAT6B, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
PfizerPF-07248144
KAT6 inhibitor
KAT6A, KAT6BPhase 3Breast Cancer; Locally Advanced or Metastatic ER+ HER2- Breast CancerJul 2027
Medical College of WisconsinIadademstat
KAT6A/KAT6B histone acetyltransferase inhibitor
KAT6A, KAT6BPhase 1Myelodysplastic SyndromesDec 2026
Olema PharmaceuticalsOP-3136
Selective inhibitor of KAT6A and KAT6B
KAT6A, KAT6BPhase 1Advanced or Metastatic ER+ HER2- Breast Cancer (mBC)May 2027
BeOne MedicinesBG-75202
KAT6A/B inhibitor
KAT6A, KAT6BPhase 1Myeloid Malignancy; Breast CancerSep 2028

Conditions

Breast Cancer (2) Myelodysplastic Syndromes (1) Locally Advanced or Metastatic ER+ HER2- Breast Cancer (1) Advanced or Metastatic ER+ HER2- Breast Cancer (mBC) (1) Myeloid Malignancy (1)

Modalities

small molecule (3), mixed (1)

Companies

Medical College of Wisconsin (1) Pfizer (1) Olema Pharmaceuticals (1) BeOne Medicines (1)

Related targets

KAT6A (4)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.